IgA nephropathy is a progressive disease where immune proteins damage the kidneys' filtering units. Treatment options include medications and lifestyle changes to help slow progression and manage ...

First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that ...

Endothelin biology remains an attractive therapeutic target in IgA nephropathy where intrarenal endothelin-1 expression is upregulated and implicated in nephron loss through vasoconstriction, ...

In this video from the National Kidney Foundation Spring Clinical Meetings, Paolo Cravedi, MD, PhD, discusses the ...

Jade Biosciences’ JADE101 Phase 1 IgA biomarker win hints at 12-week dosing, but valuation, funding, and Phase 2 2027 risks ...

IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...

VIENNA — Sibeprenlimab, a novel selective immune antibody, reduced the urine protein-to-creatinine ratio (uPCR) by more than half in patients with immunoglobulin A (IgA) nephropathy, according to an ...

Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...

IgA nephropathy mainly affects the kidneys, while IgA vasculitis can also involve your skin, joints, and digestive system. IgA vasculitis often appears suddenly with rash and pain, but IgA nephropathy ...

Vertex Pharmaceuticals recently reported that the FDA accepted its Biologics License Application for povetacicept in adults ...